NASDAQ:ANGO AngioDynamics (ANGO) Stock Price, News & Analysis $9.69 +0.34 (+3.64%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About AngioDynamics Stock (NASDAQ:ANGO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AngioDynamics alerts:Sign Up Key Stats Today's Range$9.40▼$9.6950-Day Range$8.37▼$10.8852-Week Range$5.47▼$13.50Volume226,329 shsAverage Volume558,070 shsMarket Capitalization$393.48 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewAngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.Read More… AngioDynamics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreANGO MarketRank™: AngioDynamics scored higher than 82% of companies evaluated by MarketBeat, and ranked 157th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAngioDynamics has only been the subject of 1 research reports in the past 90 days.Read more about AngioDynamics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.37) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.52% of the float of AngioDynamics has been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently increased by 1.76%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.99 Percentage of Shares Shorted4.52% of the float of AngioDynamics has been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently increased by 1.76%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment1.60 News SentimentAngioDynamics has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AngioDynamics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ANGO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AngioDynamics' insider trading history. Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGO Stock News HeadlinesShareholders in AngioDynamics (NASDAQ:ANGO) are in the red if they invested three years agoApril 8, 2025 | finance.yahoo.comAngioDynamics targets 14%-16% MedTech growth for fiscal 2025 driven by thrombectomy and NanoKnife adoptionApril 3, 2025 | msn.comThe best trading indicator for NVDARarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… April 25, 2025 | ProsperityPub (Ad)AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2025 Earnings Call TranscriptApril 3, 2025 | insidermonkey.comAngioDynamics Inc (ANGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...April 3, 2025 | gurufocus.comAngioDynamics reports Q3 adjusted EPS (8c), consensus (13c)April 3, 2025 | markets.businessinsider.comAngioDynamics up 13% in pre-market at $10.90 after Q3 results, guidance raiseApril 3, 2025 | markets.businessinsider.comQ3 2025 AngioDynamics Inc Earnings Call TranscriptApril 3, 2025 | gurufocus.comSee More Headlines ANGO Stock Analysis - Frequently Asked Questions How have ANGO shares performed this year? AngioDynamics' stock was trading at $9.16 at the start of the year. Since then, ANGO shares have increased by 5.2% and is now trading at $9.64. View the best growth stocks for 2025 here. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Wednesday, April, 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.16. The business's revenue for the quarter was down 4.3% on a year-over-year basis. Read the conference call transcript. Does AngioDynamics have any subsidiaries? AngioDynamics subsidiaries include these companies: Eximo Medical Ltd., RadiaDyne LLC, Clinical Devices, Vortex Medical, Navilyst Medical Inc., FlowMedica, Oncovionic, and others. Who are AngioDynamics' major shareholders? AngioDynamics' top institutional shareholders include Assenagon Asset Management S.A. (0.59%), Rhumbline Advisers (0.15%) and GAMMA Investing LLC (0.03%). Insiders that own company stock include James C Clemmer, James C Clemmer, Stephen A Trowbridge, Warren Nighan Jr and Dave Helsel. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AngioDynamics investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings4/02/2025Today4/25/2025Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ANGO CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees760Year Founded1988Price Target and Rating Average Stock Price Target$14.00 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+44.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,350,000.00 Net Margins-79.38% Pretax Margin-82.86% Return on Equity-7.26% Return on Assets-4.78% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.24 Sales & Book Value Annual Sales$283.32 million Price / Sales1.39 Cash Flow$4.02 per share Price / Cash Flow2.41 Book Value$5.13 per share Price / Book1.89Miscellaneous Outstanding Shares40,607,000Free Float38,281,000Market Cap$393.48 million OptionableOptionable Beta0.52 Social Links 20 Stocks to Sell NowGet This Free Report This page (NASDAQ:ANGO) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AngioDynamics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.